Opening the iTunes Store.If iTunes doesn’t open, click the iTunes icon in your Dock or on your Windows desktop.Progress Indicator
Opening the iBooks Store.If iBooks doesn't open, click the iBooks app in your Dock.Progress Indicator

iTunes is the world's easiest way to organize and add to your digital media collection.

We are unable to find iTunes on your computer. To download from the iTunes Store, get iTunes now.

Do you already have iTunes? Click I Have iTunes to open it now.

I Have iTunes Free Download
iTunes for Mac + PC

The Hepatitis C Drug Development Pipeline (Hcv Pipeline)

Research Initiative/Treatment Action! 2004, Fall, 10, 2

This book is available for download with iBooks on your Mac or iOS device, and with iTunes on your computer. Books can be read with iBooks on your Mac or iOS device.


Current hepatitis C treatment has many drawbacks, including significant side effects, high cost, and the need for injections of pegylated interferon. While the major clinical trials of pegylated interferon and ribavirin show about a 50% success rate in clearing the virus--deemed a sustained virologic response (SVR)--in real-life clinical settings, SVR rates are frequently lower. Moreover, treatment outcomes are poorer for African-Americans and for people with genotype 1, high viral loads, and/or HIV co-infection. Because of toxicities, including psychiatric side effects, treatment is often contraindicated for many people with hepatitis C. As a result, many people avoid or delay hepatitis C treatment, and only a relatively small proportion of people with hepatitis C--perhaps 10%--have been treated to date, with many failing to achieve an SVR. Thus, there is an urgent need for new, more effective, and better-tolerated treatments. The hepatitis C virus (HCV) offers a number of potential targets for drug development. HCV undergoes a relatively simple replication cycle: cell entry; translation and cleavage of viral proteins; replication of viral RNA; and assembly and release of new viruses. Each of these stages in the replication cycle are, in theory, susceptible to inhibition by new drugs, though some aspects of replication--particularly cell entry and assembly and release--are still not well understood. In addition, novel treatments could stimulate more effective immune responses targeting HCV and facilitating viral clearance. Finally, in lieu of eradicating HCV, new drugs could benefit people who do not respond to current therapy by slowing or ameliorating liver damage.

The Hepatitis C Drug Development Pipeline (Hcv Pipeline)
View in iTunes
  • 2,99 €
  • Available on iPhone, iPad, iPod touch, and Mac.
  • Category: Health & Fitness
  • Published: 22 September 2004
  • Publisher: The Center for AIDS: Hope & Remembrance Project
  • Print Length: 10 Pages
  • Language: English
  • Requirements: To view this book, you must have an iOS device with iBooks 1.3.1 or later and iOS 4.3.3 or later, or a Mac with iBooks 1.0 or later and OS X 10.9 or later.

Customer Ratings

We have not received enough ratings to display an average for this book.